PacBio is down 5.8% since the beginning of the year, and at $1.70 per share, it is trading 36% below its 52-week high of $2.65 from November 2024.

Genomics company Pacific Biosciences of California (NASDAQ:PACB) in Q4 CY2024, with sales falling 32.8% year on year to $39.22 million. Its non-GAAP loss of $0.20 per share was 15.5% below ...

Gene sequencing equipment maker PacBio plans to cut around 120 jobs and lower expenses due to fresh tariffs and reduced funding for federal health agency National Institutes of Health (NIH), it ...

MENLO PARK, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2025 financial results on ...

PacBio reported $36.9 million in Q1 revenue, beating consensus, with record consumable sales and steady Revio system pull-through. Company to cut $45–$50 million in annualized costs by year-end ...

PacBio has delivered its first Vega systems to Berry Genomics as part of an early access agreement aimed at developing and optimizing targeted assays for carrier, prenatal, and newborn screening ...

Long-read DNA sequencing technologies such as the Pacific Biosciences (PacBio) and Oxford Nanopore (ONT) platforms, have demonstrated enhanced detection of genomic variation, including Single ...